Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Eric Sbar"'
Autor:
Kazuhiko Nakagawa, Qing Zhou, Yi-Long Wu, Kay Noonan, Jesus Corral, Tao Wang, Rickard Sandin, Eric Sbar, Diana Gernhardt, Edward B. Garon, Tony Mok
Publikováno v:
Future Oncology. 15:1481-1491
Aim: This pooled safety analysis was conducted to analyze incidence and management of key dacomitinib-associated adverse drug reactions (ADRs). Patients & methods: Patients with EGFR mutation-positive advanced non-small-cell lung cancer who received
Autor:
Howard Colman, Frances Chow, Jatin P. Shah, Gregory Mundy, Andrew B. Lassman, Rebecca Harrison, Yasaman Damestani, Yang Liu, Vyshak Venur, Warren P. Mason, Nicholas Butowski, Minesh P. Mehta, Paul Duic, Sharon Tamir, Michael Schulder, John A. Boockvar, Kai Li, Yazmin Odia, Patrick Y. Wen, Erin M. Dunbar, Samuel Goldlust, Sharon Shacham, Scott R. Plotkin, Eric Sbar, Priya Kumthekar
Publikováno v:
Neuro Oncol
BACKGROUND Glioblastoma (GBM) is the most common and aggressive primary brain tumor with median overall survival of 15 months and 5-7 months for patients with newly diagnosed or recurrent disease (nGBM or rGBM), respectively. Selinexor is a first-in-
Autor:
Haris Ali, Ashwin Kishtagari, Keri Renee Maher, Sanjay Mohan, Amitabha Mazumder, Kamal Chamoun, Igor Karasik, Eric Sbar, Laura Dugon, Sharon Tamir, Xulong Wang, Josef T. Prchal, Srinivas Kiran Tantravahi
Publikováno v:
Journal of Clinical Oncology. 40:7060-7060
7060 Background: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by unregulated, clonal proliferation of a hematopoietic stem cells in the bone marrow and is commonly associated with gene mutations in JAK2, CALR, or MPL. Front-line
Autor:
Yasaman Damestani, Ruiyang Shi, Kai Li, Patrice Melikian, Shelley Haybeck, Gregory Mundy, Gursharan Gill, Shijie Tang, Eric Sbar, Tracey Duncan, Sharon Tamir, Eran Shacham, Jatin J. Shah, Sharon Shacham, Patrick Y. Wen, Erin Dunbar, Priya Kumthekar, Howard Colman, Robert Aiken, Nicholas A. Butowski
Publikováno v:
Journal of Clinical Oncology. 40:2045-2045
2045 Background: Glioblastoma (GBM) is an aggressive primary tumor with poor prognosis and survival. Patients (pts) experience debilitating symptoms that have a negative effect on quality of life (QoL). A multidisciplinary approach is necessary to fa
Autor:
Xieyang Jia, Christopher J. Hoimes, Eric Sbar, Neal D. Shore, Xiao Fang, Arlene O. Siefker-Radtke, J. Alfred Witjes, Hiroyuki Nishiyama, Ritesh S. Kataria, Andrea Necchi, Gary D. Steinberg, Matthew D. Galsky, Jens Bedke
Publikováno v:
Future Oncology, 17, 24, pp. 3137-3150
Future Oncology, 17, 3137-3150
Future Oncology, 17, 3137-3150
Contains fulltext : 237687.pdf (Publisher’s version ) (Open Access) Muscle-invasive bladder cancer (MIBC) is associated with high rates of recurrence and poor prognosis despite aggressive treatment. Neoadjuvant chemotherapy before radical cystectom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bd766c10f490958ee1800a7f90217ad
Autor:
Talia Golan, Talia Shentzer Kutiel, Maya Gottfried, Alona Zer, Aviad Zick, Ayelet Shai, Larissa Ryvo, Julia Dudnik, Nir Peled, Galia Oberkovitz, Fan Yang, Shmuel Sharoni, Changting Meng, Dayana Michel, Eric Sbar, Jatin J. Shah, Michael Kauffman, Sharon Shacham, Ravit Geva
Publikováno v:
Journal of Clinical Oncology. 40:110-110
110 Background: Single agent selinexor, an oral selective inhibitor of nuclear export (SINE), showed activity against heavily pretreated CRC with RAS mutations (mut) or wildtype (wt) in 2 clinical studies. In preclinical studies, selinexor showed sup
Autor:
Seiji Niho, Tony Mok, Eric Sbar, Jane Liang White, Min Lee, Ki Hyeong Lee, Ying Cheng, Tao Wang, Yi-Long Wu, Kazuhiko Nakagawa, Jesus Corral, Xiangdong Zhou, Adam Pluzanski, Rafael Rosell, Maria Rita Migliorino, R. Linke
Publikováno v:
Journal of Clinical Oncology. 36:2244-2250
Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naïve patients with advanced non–small-cell lung cancer (NSCLC) and activating mutations in EGFR, reported significant improvement in progr
Autor:
Jane Liang White, Seiji Niho, Tony Mok, R. Linke, Adam Pluzanski, Sashi Nadanaciva, Kazuhiko Nakagawa, Xiangdong Zhou, Ying Cheng, Jesus Corral, Ki Hyeong Lee, Tao Wang, Rafael Rosell, Rickard Sandin, Eric Sbar, Fumito Tsuji, Yi-Long Wu, Maria Rita Migliorino
Publikováno v:
The Lancet Oncology. 18:1454-1466
Summary Background Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line treatment of patients with
Autor:
Eric Sbar, Helena A. Yu, Susan Quinn, Nagdeep Giri, David E. Gerber, Ronald B. Natale, Giuseppe Giaccone, Mark A. Socinski, Hui Zhang, Myung-Ju Ahn, Byoung Chul Cho
Publikováno v:
Lung Cancer
Background Dacomitinib is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Pre-clinical data suggest that intermittent pulsatile dosing of dacomitinib may result in inhibition of EGFR T790M. M
Autor:
Stephen T. Sonis, Sashi Nadanaciva, Mario E. Lacouture, Edward B. Garon, Tao Wang, Dong Wan Kim, Nagdeep Giri, Eric Sbar, Joe O'Connell, Aminah Jatoi, Dorothy M. K. Keefe, Diana Gernhardt, Jim P. Doherty, Byoung Chul Cho
Publikováno v:
Lung Cancer. 106:76-82
Dacomitinib is a pan-HER inhibitor for advanced non-small-cell lung cancer (NSCLC). We explored the impact of a planned 4-day dacomitinib dose interruption on plasma exposure of dacomitinib and adverse events (AEs) of interest in Cohort III of the AR